Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 9Carcinoma, Non-Small-Cell Lung 9Melanoma 7Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Neoplasms 4Carcinoma, Transitional Cell 4Neoplasm Metastasis 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unresectable or Metastatic Solid Tumors 1Solid Tumors 1Skin Neoplasms 1Recurrence 1Microsatellite Instability 1Mesothelioma 1Hematologic Neoplasms 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1

Interventions

pembrolizumab 5atezolizumab 2Nivolumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Microsatellite Instability × epacadostat × Clear all
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡